<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488071</url>
  </required_header>
  <id_info>
    <org_study_id>14178A</org_study_id>
    <secondary_id>2011-002362-21</secondary_id>
    <nct_id>NCT01488071</nct_id>
  </id_info>
  <brief_title>A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication</brief_title>
  <acronym>REVIVE</acronym>
  <official_title>A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate whether vortioxetine (10 or 20 mg/day) is
      at least as effective as agomelatine (25 to 50 mg/day) in patients with depressive symptoms
      that showed inadequate response to Serotonin Reuptake Inhibitors (SRI) antidepressants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in MADRS Total Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MADRS Total Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A Total Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAM-A Total Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CGI-S Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CGI-S Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Status Using CGI-I Score at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Status Using CGI-I Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Respond at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Respond at Week 12 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score &lt;=10)</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score &lt;=10)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDS Total Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDS Total Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vortioxetine 10 mg or 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Agomelatine 25 mg or 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine (Lu AA21004)</intervention_name>
    <description>encapsulated tablets, daily, orally</description>
    <arm_group_label>Vortioxetine 10 mg or 20 mg</arm_group_label>
    <other_name>Brintellix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agomelatine</intervention_name>
    <description>encapsulated tablets, daily, orally</description>
    <arm_group_label>Agomelatine 25 mg or 50 mg</arm_group_label>
    <other_name>Valdoxan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is being treated with a serotonin reuptake inhibitor (SRI) antidepressant
             (monotherapy) that was prescribed to treat Major Depressive Episode (DSM-IV-TR
             criteria)

          -  The response to the current SRI treatment is inadequate and patient agrees to
             discontinue the current SRI at the baseline

          -  Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥22 at the Screening
             Visit and Baseline

          -  The patient, if a woman, must: agree not to try to become pregnant during the study,
             AND use adequate, highly effective contraception

        Exclusion Criteria:

          -  The patient has any current Axis I disorders (DSM-IV criteria) other than Major
             Depressive Disorder (MDD), General Anxiety Disorder (GAD) and Social Anxiety Disorder
             (SAD)

          -  The patient is at significant risk of suicide

          -  The patient is currently receiving formal psychotherapy or other psychoactive
             medications

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>December 19, 2013</results_first_submitted>
  <results_first_submitted_qc>February 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2014</results_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Multimodal antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
    <mesh_term>S 20098</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In- or outpatients who had been treated with antidepressant selective serotonin reuptake inhibitor (SSRI) or selective noradrenaline reuptake inhibitor (SNRI) monotherapy that was prescribed to treat a single episode of Major Depressive Disorder (MDD) or recurrent MDD.</recruitment_details>
      <pre_assignment_details>The study will consist of a screening period of 4 to 10 days before the Baseline Visit, followed by a 12-week treatment period with vortioxetine or agomelatine. A safety follow-up will be done approximately 4 weeks after the Completion/Withdrawal Visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vortioxetine 10 mg or 20 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="P2">
          <title>Agomelatine 25 mg or 50 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="253">all-patients-treated set (APTS)</participants>
                <participants group_id="P2" count="242">APTS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative or Other Reason(s)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age and Gender: All-patients-treated set (APTS) – all patients in the APRS who took at least one dose of investigational medicinal product (IMP).
Study Specific Characteristics: Full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the MADRS total score.</population>
      <group_list>
        <group group_id="B1">
          <title>Vortioxetine 10 mg or 20 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="B2">
          <title>Agomelatine 25 mg or 50 mg</title>
          <description>encapsulated tablets, daily, orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="253"/>
            <count group_id="B2" value="242"/>
            <count group_id="B3" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.0" spread="12.4"/>
                    <measurement group_id="B2" value="45.6" spread="12.4"/>
                    <measurement group_id="B3" value="46.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MADRS: Baseline Total Score</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 - 60. The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="4.4"/>
                    <measurement group_id="B2" value="28.7" spread="4.0"/>
                    <measurement group_id="B3" value="28.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAM-A: Baseline Total Score</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="6.3"/>
                    <measurement group_id="B2" value="21.4" spread="6.2"/>
                    <measurement group_id="B3" value="21.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CGI-S Baseline Severity Score</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the patient is more ill.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="0.6"/>
                    <measurement group_id="B2" value="4.4" spread="0.6"/>
                    <measurement group_id="B3" value="4.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SDS Total Baseline Score</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="5.3"/>
                    <measurement group_id="B2" value="19.3" spread="5.2"/>
                    <measurement group_id="B3" value="19.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in MADRS Total Score at Week 8</title>
        <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>full-analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score at Week 8</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
          <population>full-analysis set (FAS)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.53" spread="0.48"/>
                    <measurement group_id="O2" value="-14.38" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Mixed model for repeated measurements (MMRM), using all available data, with a freely varying mean and covariance structures and with treatment, week, and site group as fixed factors and the baseline score as a covariate. The model also included interaction between week and baseline score, as well as interaction between week and treatment.
Non-inferiority, upper limit of Confidence Interval should not exceed 2.</non_inferiority_desc>
            <p_value>0.0018</p_value>
            <p_value_desc>Under established non-inferiority the p-value is not adjusted.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MADRS Total Score at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score at Week 12</title>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.95" spread="0.50"/>
                    <measurement group_id="O2" value="-16.92" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.45</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A Total Score at Week 8</title>
        <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A Total Score at Week 8</title>
          <description>The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56; higher score indicates greater anxiety, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.68" spread="0.39"/>
                    <measurement group_id="O2" value="-9.79" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>-0.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAM-A Total Score at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAM-A Total Score at Week 12</title>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.52" spread="0.40"/>
                    <measurement group_id="O2" value="-11.59" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.04</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CGI-S Score at Week 8</title>
        <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CGI-S Score at Week 8</title>
          <description>The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating. Higher score indicates that the subject is more ill, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="0.07"/>
                    <measurement group_id="O2" value="-1.55" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CGI-S Score at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CGI-S Score at Week 12</title>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="0.07"/>
                    <measurement group_id="O2" value="-1.93" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0075</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
        <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.</description>
        <time_frame>Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Status Using CGI-I Score at Week 8</title>
          <description>The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment. Higher score = more affected.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.06"/>
                    <measurement group_id="O2" value="2.22" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Status Using CGI-I Score at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Status Using CGI-I Score at Week 12</title>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.06"/>
                    <measurement group_id="O2" value="1.99" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0055</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Respond at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS, last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Respond at Week 8 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
          <population>FAS, last observation carried forward (LOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Wald's Test. No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Respond at Week 12 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Respond at Week 12 (Response Defined as a &gt;=50% Decrease in the MADRS Total Score From Baseline)</title>
          <population>FAS, LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8"/>
                    <measurement group_id="O2" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Wald's Test. No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score &lt;=10)</title>
        <time_frame>Week 8</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Are in Remission at Week 8 (Remission is Defined as a MADRS Total Score &lt;=10)</title>
          <population>FAS, LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <p_value_desc>Wald's Test. No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score &lt;=10)</title>
        <time_frame>Week 12</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Are in Remission at Week 12 (Remission is Defined as a MADRS Total Score &lt;=10)</title>
          <population>FAS, LOCF</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2"/>
                    <measurement group_id="O2" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Wald's Test. No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDS Total Score at Week 8</title>
        <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDS Total Score at Week 8</title>
          <description>The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe, thus, a negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.28" spread="0.53"/>
                    <measurement group_id="O2" value="-7.06" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDS Total Score at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine 10 mg or 20 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
          <group group_id="O2">
            <title>Agomelatine 25 mg or 50 mg</title>
            <description>encapsulated tablets, daily, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDS Total Score at Week 12</title>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.99" spread="0.55"/>
                    <measurement group_id="O2" value="-9.24" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0209</p_value>
            <p_value_desc>No adjustments for multiple comparisons were made.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The same MMRM methodology as for the primary endpoint was used.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.75</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.23</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vortioxetine</title>
        </group>
        <group group_id="E2">
          <title>Agomelatine</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="242"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="242"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of this study will be published. Authors of the primary publication based on this study must fulfil the criteria defined by the International Committee of Medical Journal Editors (ICMJE). The primary publication must be published before any secondary publications are submitted for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+45 36301311</phone>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

